Use of the axillary suspensory ligament as an adipo-fascial flap for total subpectoral implant coverage in breast reconstruction: a retrospective review
- Publisher:
- Springer Nature
- Publication Type:
- Journal Article
- Citation:
- European Journal of Plastic Surgery, 2025, 48, (1), pp. 82
- Issue Date:
- 2025-12-01
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Background: Subpectoral breast reconstruction following mastectomy requires adequate soft tissue coverage to prevent prosthetic complications such as extrusion, capsular contracture, and poor aesthetic outcomes. The suspensory ligament of the axilla (SLA), a fascial structure often overlooked, may offer a novel autologous solution for complete implant coverage without the morbidity or cost associated with acellular dermal matrices or synthetic mesh. Methods: This study assessed postoperative outcomes and complication rates in patients undergoing alloplastic breast reconstruction utilizing the SLA as an adipo-fascial flap for total subpectoral coverage. Twenty patients (24 breasts) underwent immediate reconstruction with the SLA technique between January 2018 and January 2024. Results: The cohort had an average age of 49 years and a mean follow-up duration of 12 months. A total complication rate of 16.6% was observed, including 8.33% minor complications and 8.33% major complications. No cases of skin flap necrosis, implant extrusion, hematoma, or donor site morbidity were reported. Patient satisfaction based on informal self-reporting during follow-up was generally high, with 75% reporting their aesthetic outcome as very good. Conclusion: Early findings suggest the SLA-based subpectoral reconstruction technique may offer a safe, cost-effective alternative for achieving total prosthetic coverage. It eliminates the need for foreign materials, preserves muscle function, and demonstrates a low complication rate. While early outcomes are promising, prospective studies with larger cohorts are needed to further validate its long-term efficacy and safety. Level of evidence: Level IV, therapeutic study.
Please use this identifier to cite or link to this item:
